AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 71 min read$MAIA

MAIA Biotechnology (MAIA) Completes Phase 2 Part C; Phase 3 65% to Year-End Target

MAIA Biotechnology completed enrollment for Part C of its Phase 2 THIO-101 trial and reported 65 patients enrolled in its Phase 3 THIO-104 trial, targeting 100 by 2026. Interim analysis is planned for 2027, according to the company.

Original reporting
tradingview.com
Published Oct 7, 2026, 12:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 12:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
MAIA Biotechnology (MAIA) Completes Phase 2 Part C; Phase 3 65% to Year-End Target — source image
Source · tradingview.com
Decision brief

The 30-second read

$MAIABullishMed
01

Why it matters

The enrollment update reduces execution risk and may attract short‑term buying pressure ahead of the interim analysis scheduled for 2027.

02

Market read

Trial enrollment news is a material catalyst for a biotech stock, offering a near‑term trade idea based on upcoming data releases.

03

What to watch

Potential competition from other NSCLC therapies and regulatory timelines are not addressed.

Relevance 8/10Novelty 8/10Timing: today

Background

MAIA Biotechnology is a clinical‑stage company focused on novel therapies for non‑small cell lung cancer.

Company-level read

Ticker impact

$MAIABullishHigh confidence
Context

MAIA Biotechnology reported completion of enrollment for Part C of its THIO-101 Phase 2 NSCLC trial and that Phase 3 enrollment has reached 65 patients toward a 100‑patient year‑end target.

Expected impact

likely modest upside as investors price in the trial progress and anticipate Phase 3 data

Evidence & confidence

Trial enrollment is a concrete forward‑looking metric; positive enrollment typically supports biotech valuations ahead of data releases.

Market effects

Sector

Strengthens the oncology biotech sector by showing continued pipeline execution.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minor global impact; primarily relevant to biotech and pharma investors.

Counterpoint

What could challenge this read

If the Phase 3 enrollment pace slows or data later disappoint, the current optimism could reverse.

Key entities

  • company
    MAIA Biotechnology

    Developer of THIO‑101 and THIO‑104 oncology candidates.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 7
$MAIAMedAI 8/10

MAIA Completes THIO-101 Part C Enrollment; Phase 3 Enrollment Hits 65%

MAIA Biotechnology (MAIA) announced completing enrollment for Part C of its Phase 2 THIO-101 trial and 65% completion for its Phase 3 THIO-104 trial, both evaluating ateganosine in NSCLC. The company reported a 90.5% interim disease control rate for the combination therapy. MAIA aims to enroll 100 patients in THIO-104 by 2026, with an interim analysis planned for 2027. The FDA granted Fast Track designation to ateganosine in July 2025. MAIA shares are up 0.85% at $1.20.

rttnews.com2 min
OCT 7
$MAIAMedAI 9/10

MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer

MAIA Biotechnology (NYSE American: MAIA) reported milestones in its Phase 2 and Phase 3 trials for ateganosine, a telomere-targeting agent for non-small cell lung cancer (NSCLC). Enrollment is complete for Part C of the Phase 2 trial, with 90.5% interim disease control reported. The Phase 3 trial has reached 65% of its 100-patient enrollment target. The FDA granted Fast Track designation to ateganosine in July 2025.

globenewswire.com2 min
SEP 16
$MAIAMedAI 8/10

MAIA Biotechnology, Inc.: MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial

MAIA Biotechnology, Inc. (NYSE American: MAIA) dosed the first U.S. patient in its Phase 2 THIO-101 trial for ateganosine in third-line non-small cell lung cancer (NSCLC). The trial is funded by a $2.3 million NIH grant. Ateganosine has FDA Fast Track designation and showed promising overall survival data in prior trials.

finanznachrichten.de2 min